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The development of and application of pharmacogenetics in health care promises to move genetic testing into a new era. Through the application of pharmacogenetics, it will soon be possible to characterise variation between DNA of patients to predict their responses to specific medicines. It is widely expected that the availability of predictive medicine response profiles will change the practice and economics of healthcare. 1 A move away from the strategy of producing a medicine for general use by genotypically diverse patient populations will increase the number of drugs that need to be designed to target a more segregated patient population. Thus medicines for general use will need to be replaced by subsets of compounds that comprise a major drug class. The consequent introduction of pharmacogenetics into the clinical setting will bring genetic testing into much wider usage. Although there is disagreement about the degree to which the pharmacogenetic approach will become the standard for the development of new medicines and over what time scale, there is growing recognition of the need to anticipate the ethical issues that are likely to be raised. This article focuses on three key aspects: the existing ethical framework for genetic testing with a particular emphasis on consent, whether pharmacogenetic testing is distinctive from other kinds of genetic testing and the ethical issues posed by the genotypic stratification of patients in clinical trials.
Experience of genetic testing has developed over the past decade through the identification of an increasing number of single genes for rare diseases. During this period, genetic testing and screening services have become well established in most developed countries. Prenatal screening, screening of neonates and screening of adults for carrier status and late onset disorders are now available for several genetic diseases. The development of these services has taken place against a background of extensive debate about the ethical issues that they raise. Accumulating experience and debate has led to the formulation of ethical guidelines for genetic testing by several advisory bodies, including national bioethics commissions and similar bodies, international organisations such as the Council of Europe, professional bodies and many others. These guidelines are the starting point for the expansion of genetic testing that pharmacogenetics will bring. Guidance for genetic testing has been based largely on the experience derived from the diagnosis of single gene disorders, including Huntington's disease, cystic fibrosis, phenylketonuria and the thalassaemias. More recently, experience has widened to include testing for certain cancers where the prediction of risk may be less certain as in the case of the inherited forms of breast cancer (BRCA1, BRCA2). Many genes which confer susceptibility to a wide range of complex diseases, will be identified over the next 5-10 years. However, to what extent genetic testing for complex diseases will make it possible to individualise risk figures, is unclear.
The public perception of genetic testing is one that is inevitably associated with disease, both the rare diseases and more recently and somewhat prematurely, the more common complex diseases. While the benefits of genetic testing are generally evident to those who seek to be tested, whether for adult carrier status or for the purpose of pre-natal testing, the procedure is increasingly associated in the public's mind with concerns over privacy and confidentiality. Pharmacogenetic testing may be perceived by the public rather differently for two reasons. First, because it is associated with the clear and readily accessible concept of the minimisation of side effects from medicines and second, because it is concerned with genetic polymorphisms rather than mutations for rare diseases and therefore has the potential to affect relatively large numbers of patients.
The principal ethical issues that have been raised by genetic testing in monogenic disease have concerned patient consent and confidentiality, prenatal testing, the testing of children and the mentally incompetent and research procedures. Some of these ethical issues apply at several levels. For example, confidentiality of patient information in relation to genetic testing may raise questions that concern family members or issues that involve external agents such as the insurance industry or employers. In the case of pharmacogenetics, many of the guidelines established for other kinds of genetic testing will apply in the clinical setting. For example, in the case of consent, the same principles will broadly apply (see Box 1) .
In a rapidly evolving field such as pharmacogenetics, it is inevitable that research and clinical work will be closely entwined. Genetic analysis of populations to identify genes of interest need not pose particular ethical difficulties, provided that appropriate guidelines are followed. The more complex ethical issues may be raised when DNA samples collected for research, including clinical trials, yield
Box 1. Genetic testing and consent
An important principle in ethics is the respect for human beings and their autonomy and dignity. This ethical principle underlies the legal requirement to seek consent prior to any genetic counselling or testing of adults. In general any invasive procedure undertaken without consent will be illegal. It is widely recognised that fully informed consent is an unattainable ideal and that the ethically significant requirement is not that consent be complete, but that it be genuine. Obtaining genuine consent requires health professionals to do their best to communicate accurately and in an understandable way the purpose and implications of the procedure as well as the risk. It is generally accepted that particular care needs to be taken when obtaining consent from minors and the mentally incompetent and this will apply in pharmacogenetic testing as in other areas of genetic testing. In general, the law permits diagnostic testing of children without their consent, only when it is in the child's best interest.
For an adult person deemed mentally incompetent to make his or her treatment decisions, a doctor must also act in the patient's 'best interest'. In the context of pharmacogenetics, genotyping the patient could be justified as part of the treatment procedure.
clinically significant information. How should such information be handled? For those who have a specific polymorphism (eg non-responders to a medicine or an associated disease susceptibility) there could be implications for a relative. The ethical difficulty arises because the process of obtaining informed consent required for research does not usually include consent for the disclosure of identifiable data to clinics outside the strict environs of research. To provide individuals with research information about unexpected gene mutations which they might or might not carry could be to give them information that they would choose not to have and for which they had not been counselled. 2 As a general rule it has been suggested by a number of professionals that research participants should be told that individual information about
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Genetic tests have been largely based on the detection of specific mutations in genes known to be implicated in a particular disease. In the case of phamacogenetic testing, the nature of the information being analysed promises to be rather different. Not only will the majority of genes involved be specific to drug metabolism rather than disease, the variants of interest within populations will be relatively common polymorphisms rather than rare mutations. Further, it appears some medicine response profiles may be based on single nucleotide polymorphism (SNP) linkage disequilibrium profiles. SNPs are the simplest kind of DNA polymorphism and chip technologies are already available for the accurate genotyping of large numbers of SNPs. The application of wholegenome SNP linkage disequilibrium mapping to participants during phase II clinical trials of a medicine may enable the selection of multiple small regions where the SNPs are in linkage disequilibrium and associated with efficacy and common adverse event phenotypes. 1 The use of abbreviated SNP profiles to assess the medicine response of patients would avoid the ethical implications that may arise when a patient is tested for a diseasespecific mutation or a disease susceptibility gene where the emphasis is on clinical diagnosis and prediction of risk. With SNP profiles although the patient's DNA would have been tested to enable the selection of a particular medicine and a dosing schedule, no genetic information about the patient's disease per se would be provided. However, some researchers have taken the view that the SNP approach would result in a very large genotyping burden and that it may not be as reliable as originally suggested. 3, 4 A more direct approach would involve studying polymorphisms which are known to be involved in disease and drug pathways. 5 There may be some instances where a gene involved in drug metabolism also has a role in disease susceptibility. For example a number of recent studies have suggested that the ApoE genotype can predict responses to therapeutic doses of the cholinomimetic drug, tacrine. 6 Clearly if the risk of developing disease is significant, then there will be a need to advise the patient accordingly. In the clinical setting, this will be relatively straightforward provided the patient has received prior counselling. In the research context (including clinical trials) advising patients of an unexpected disease risk requires careful planning beforehand. A number of bodies have concluded that genetic testing for susceptibility genes which offer relatively low predictive or diagnostic certainty should be discouraged unless there is clear medical benefit to the patient. 2 As pharmacogenetics becomes increasingly well established in the process of drug discovery, clinical trials will require patient stratification. This raises a number of questions which researchers would not normally need to consider in a conventional trial where a genotypically diverse patient population is being tested with a single medicine. Clearly, pharmacogenetic profiling will identify patients who do not respond to specific treatments as well as those who are at high risk from side effects. Researchers will need to decide whether high-risk patients identified in research should be informed of their status. Medicine response profiles are likely to be identified in phase II trials and will lead to the selection of stratified patient groups for phase III. Those patients who have poor efficacy predictions on the basis on phase II data will clearly benefit by exclusion from phase III.
Indeed it would be unethical to include such patients in further trials of the same medicine. As a result, phase III trials are expected to be smaller, faster and more efficient. 7 Consequently they are less likely to detect the rare adverse events and there is likely therefore to be a greater need for post approval surveillance through the use of blood spots. Questions are also raised over nonresponders who may receive greater exposure to a drug. Regulatory agencies and the pharmaceutical companies will need to work together to plan and examine methods to evaluate fewer total patients in smaller more rapid clinical trials, while at the same time enhancing drug monitoring systems.
What are the ethical implications of the genotypic sub-grouping of populations? Segmenting a population by genotype rather than socio-economic class, blood group or gender raises issues related to stigmatisation, privacy and confidentiality. It is well known that the frequency of genetic variations in medicine response profiles differs between ethnic groupings. 8, 9 For example, the anti-tuberculosis drug, Isoniazid, is inactivated by acetylation and the capacity of individuals to inactivate the drug depends on their genotype at the N-acetyl transferase 2 (NAT2) locus. Slow acetylation causes toxicity. Less than 20% of individuals in the Japanese population have the slow acetylator phenotype compared to 50% of the majority of Caucasian populations and 80% of some populations from the Middle East. 10 More recently, the effect of race has been shown to be significant in patient response to an important class of drugs used in heart failure. Enalapril, an angiotensin-converting-enzyme inhibitor, appeared to be more effective in reducing the risk of hospitalisation and death in whites than in blacks. 11 The authors of the study acknowledged that racial categorisation may only be a surrogate marker for genetic or other factors. 12 In general, pharmacogenetic data, particularly when it is in the form of abbreviated SNP profiles would seem to provide little opportwww.nature.com/tpj unity for stigmatisation. However, even a weak association of any particular variant with a susceptibility to a characteristic perceived as 'socially undesirable' such as addiction or alcoholism could be stigmatising and sensitivity will need to be exercised in pharmacogenetic analyses which are based on racial groupings. The racial variation in medicine response profiles however emphasises the importance of assessing different racial groups in their response to new medicines so that physicians can make better judgements about treatments for individual patients.
A common concern about the implications of genetic testing is whether external agencies may be able to obtain access to research information. Researchers do have a responsibility to ensure that their raw individualised data will not be used for any other purpose and the withholding of research data is likely to prove defensible in all but the cases of greatest public interest. Particular care should be taken to ensure that genetic information obtained during participation in research should not be made available to employers or insurers. While it seems unlikely that genetic data for the evaluation of medicine response profiles will be of value to employers and providers of life insurance, there could be negative implications for some individuals whose healthcare is provided through health insurance rather than a socialised healthcare system. One concern about the explicit identification of non-responders in the clinical or primary care setting is that they may be discriminated against by health insurance providers. If comparable alternatives to the medicine in question are not available, healthcare management of the patient may be more costly. Genotyping could lead to some patients being characterised as 'difficult to treat' or 'more expensive to treat'. 13 Thought needs to be given as to whether these patients, if identified in a clinical trial, would be required to disclose the information to their healthcare providers.
The potential benefits of patient genotyping will be improved safety of medicines and improved efficacy.
Adverse reactions to medicines is the fourth leading cause of death in the USA and patient profiling has the potential to lead to a significant reduction in adverse drug reaction. Many patients are also refractory to drug treatment or receive limited benefit and therefore treatment based on pharmacogenetic profiling will lead to improved efficacy. While the development of pharmacogenetics does not appear to raise new ethical issues, careful assessment of research procedures and the management of genetic information is needed. In encouraging debate on these issues, a clear distinction needs to be made between genetic testing for monogenic disease and disease susceptibility and genetic testing for pharmacogenetic profiles. 
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